Pepper Hamilton Represents Palvella Therapeutics in $45M Series C Financing
Pepper Hamilton LLP represented Palvella Therapeutics, Inc., a rare disease biopharmaceutical company focused on developing and commercializing pathogenetically targeted therapies for serious genetic diseases with no approved treatments, in the closing of an oversubscribed $45 million Series C financing.
Proceeds from the Series C financing will support the advancement of PTX-022 (QTORIN™ 3.9 percent rapamycin anhydrous gel) for the treatment of adults with pachyonychia congenita (PC), a rare, chronically debilitating and lifelong genetic disease estimated to affect more than 9,000 individuals in the United States.
The Pepper Hamilton team representing Palvella was led by partners Christopher S. Miller and N. Nicole Stakleff, members of the firm’s Health Sciences Department. The team also included partner Timothy C. Atkins; associates Keith Y. Guo, Gregory P. Katz, Morgan Klinzing, Thomas E. Mitchell and Jessica X.Y. Rothenberg; attorney Lori E. Harrison; and paralegals Jeanne M. Ledwell and Dawn A. MacFarline.
Read more about the financing at https://philadelphia.citybizlist.com/article/612260/palvella-therapeutics-completes-45m-series-c-financing.